


EBV⁺ ALK⁺ large B-cell lymphoma

Hui Liu and Shimin Hu, The Affiliated Hospital of Xuzhou Medical University, The University of Texas MD Anderson Cancer Center



A 42-year-old man who had no known immunodeficiency presented with a 4-day history of a right cervical mass. A computed tomography scan revealed bilateral cervical, supraclavicular, mediastinal, abdominal, and retroperitoneal lymphadenopathy. A cervical lymph node biopsy showed a neoplasm with a striking sinusoidal growth pattern (panels A and B; hematoxylin and eosin stain; original magnification $\times 100$ [A] and $\times 400$ [B]). The tumor cells had a plasmablastic appearance with eccentric nucleus, distinct nucleoli, and abundant eosinophilic cytoplasm. They were positive for ALK, CD138, MUM1, and EBER (90%), weakly positive for CD22 and κ , and negative for PAX5, CD19, CD20, CD79a, λ , CD3, CD5, CD43, LMP1, and EBNA2 (panels C-E; original magnification $\times 400$). The Ki-67 proliferation rate was $\sim 70\%$. FISH studies revealed ALK gene rearrangement

(panel F) and no *MYC* gene rearrangement. Serum Epstein-Barr virus (EBV) viral load was 4.12×10^4 IU/mL. The patient was diagnosed with EBV⁺ ALK⁺ large B-cell lymphoma (LBCL), EBV latency type I. He received EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) for 6 cycles and achieved complete remission. He was free of disease 65 months after the initial diagnosis.

ALK⁺ LBCL is a rare entity, with ~ 200 cases reported in literature. This is the first reported case of EBV⁺ ALK⁺ LBCL. This case raises the awareness of this rare disease among the differential diagnosis of EBV⁺ LBCL and expands the spectrum of EBV⁺ lymphoma currently recognized in the World Health Organization classification.